HMG-CoA Reductase Inhibitors and the Risk of Fractures

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in reducing the risk of cardiovascular morbidity and mortality in patients with hyperlipidemia.^1-6 In addition to the ability of statins to decrease serum cholesterol levels, recent studies in animals showed that these agents have pharmacologic effects on bones. Mundy et al⁷ recently reported substantial increases in bone formation and trabecular bone volume in female rats after 5 weeks of oral simvastatin administration. Additional animal studies indicated that statins may decrease the severity of steroid-induced osteonecrosis.^8,9